Maj.Gen. (Rtd.) P.D. Sheena from Thrissur wins Florence Nightingale Award 2025
Maj. Gen.(Rtd.) Sheena P. D., a native of Vadama in Mala, Thrissur district, has won the prestigious Florence Nightingale Award 2025.
President of India Droupadi Murmu conferred the award upon her during a ceremonial event held at Rashtrapati Bhavan in New Delhi on Friday.
After an illustrious career spanning nearly 40 years, she retired as Additional Director General of Military Nursing Service recently.
Maj.Gen.(Rtd.) Sheena began her illustrious career in 1985 when she joined the Military Nursing Service. In 1994, she specialised in Oncology Nursing from the renowned Tata Memorial Hospital in Mumbai. She earned a Postgraduate Diploma in Hospital and Healthcare Management from Symbiosis Institute, Pune, in 2012.
Her exceptional service and leadership led to various administrative appointments within the Armed Forces. She was selected for administrative duties and served as the Principal of the School of Nursing at the Military Hospital in Secunderabad under the Southern Command, and later as the Principal of the College of Nursing at the Command Hospital in Kolkata under the Eastern Command.
At the Integrated Headquarters of the Army in Delhi (DGMS), she held key staff roles including Colonel Training (MNS) and Brigadier Admin (MNS). Her distinguished career spans across multiple military hospitals throughout India, where she has made significant contributions. During her tenure as a Brigadier, she was posted as the Principal Matron at the Northern Command Hospital in Udhampur, Kashmir, further proving her ability to serve in challenging environments.
The National Florence Nightingale Award, instituted by the Ministry of Health and Family Welfare, honours the dedication, compassion, and resilience that define the nursing profession. Each award includes a Certificate of Merit, a cash prize of ₹1,00,000, and a medal. This year, 15 nurses from various regions and healthcare settings were honoured for their exemplary service.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New Indian Express
2 days ago
- New Indian Express
Gogoi named state Congress chief, thanks CM Sarma
When Lok Sabha MP from Jorhat Gaurav Gogoi took charge as the Assam Congress president on Tuesday, he couldn't help but take a not-so-subtle dig at CM Himanta Biswa Sarma, who has been lobbing one attack after another at him. Gogoi quipped, 'Had the Chief Minister not been so busy with me in the last two to three years, my party would not have entrusted me with this responsibility.' His appointment as the party's state unit chief comes in the backdrop of serious allegations made by Sarma that Gogoi's British wife is linked with Pakistan spy agency ISI. Bengal man booked for denigrating Hindu deity The Assam police have registered a case against a man from Kolkata, Wazahat Khan Qadri Rashidi, for his alleged disparaging remarks about Goddess Kamakhya. Chief Minister Himanta Biswa Sarma took a serious view of the matter and wrote on X, 'Reference to unacceptable comments made by an individual against Devi Maa Kamakhya, a case has been registered by @assampolice and we will seek West Bengal Govt's cooperation in bringing the individual to Assam to face the law.' Sarma said the Assam government would request the West Bengal government to hand the accused over to Assam police. Health visitor from state gets Nightingale Award Binapani Deka, a lady health visitor from Assam's Nalbari, has brought laurels to the state by winning a National Florence Nightingale Award, an honour instituted by the Ministry of Health and Family Welfare that recognises the dedication, compassion and resilience that define the nursing profession. She was presented the award by President Droupadi Murmu at a recent ceremony. CM Sarma described it as a proud moment for Assam. This year, 15 nurses from various regions and healthcare settings were feted for their exemplary service in strengthening public health delivery and commitment to community welfare. Prasanta mazumdar Our correspondent in Guwahati prasantamazumdar@
Time of India
3 days ago
- Time of India
Trump's prescription drug price cuts unlikely to hit Indian pharma exports significantly: Crisil Ratings
US President Donald Trump 's executive order on reducing prescription drug prices will have a limited impact on Indian pharma companies, according to a report by Crisil Ratings . Citing the reason behind its observation, the credit rating firm in its report said that despite India exporting over half of its pharmaceutical output, the bulk comprises low-priced generic drugs, which already operate on razor-thin margins, leaving little room for further price cuts to materially affect revenues. In over half of the pharmaceutical output, one-third goes to the United States. India exports 54 per cent of its pharmaceutical production, of which nearly a third is to the US. Around 85 per cent of the exports to the US comprise formulations, largely generics, while sales from biosimilars and innovator drugs remain low. Also Read: US FDA approves Moderna's next-gen COVID vaccine for adults 65 or older Generic pharma drugs account for 90 per cent of the prescription sales volume but only 13 per cent of the value spending in the US. Generic drug prices in the US are very low and have lower prices in comparison to economically peer countries. Live Events The executive order issued in the United States aims to reduce the prices of prescription drugs by 30-80 per cent through the adoption of a Most Favoured Nation (MFN) pricing model. The US Department of Health and Human Services (HHS) has outlined the initial steps to be taken to implement this policy, involving identification of manufacturers expected to align the prices of branded products, which do not currently have generic or biosimilar competition, with the lowest price among a set of economic peer countries of the US. Trump's executive order primarily targets high-margin branded innovator drugs and excludes generics and biosimilars. "The MFN model is unlikely to significantly affect the bulk of India's exports," the report added. Also Read: Zydus gets USFDA nod for generic IBS-D treatment drug It further added, "However, potential indirect impact, through lower growth prospects for upcoming generic versions of innovator drugs going off patent, due to lower price differential post price reductions of the innovator drugs, would bear watching." However, a few formulation companies with niche presence in the branded innovator drug segment can face some pricing risk. "API exports (15 per cent of India's pharma exports) are expected to be broadly unaffected, as it is not a major cost for high-margin originator drugs, abating concerns of pricing pressure," the report added. Additionally, the policy may create opportunities for contract manufacturing organisations, which constitute 8 per cent of India's pharma market. "The policy may create opportunities for CMOs ( 8 per cent of India's pharma market), with orders expected to improve as global pharma companies seek to lower production costs by outsourcing. While this could support volumes, the pressure on pricing may result in renegotiation of contract rates, compressing margins," the report further added.
Time of India
4 days ago
- Time of India
Zydus gets USFDA nod for generic IBS-D treatment drug
Zydus Lifesciences on Monday said it has received approval from the US health regulator to market a drug for the treatment of irritable bowel syndrome with diarrhoea in adults. The company has received tentative approval from the US Food and Drug Administration (USFDA) for Rifaximin Tablets (550 mg), the drug manufacturing firm said in a regulatory filing. Rifaximin tablets are indicated for the treatment of irritable bowel syndrome with diarrhoea ( IBS-D ) in adults. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Access all TV channels anywhere, anytime Techno Mag Learn More Undo As per the IQVIA MAT March sales data, Rifaximin tablets had an annual sales of USD 2,672.9 million in the US. Shares of Zydus Lifesciences were trading at Rs 926.05 apiece, 0.41 per cent down from previous close, on BSE.
